ARTICLE | Company News
Merck KGaA, Peptimmune deal
September 26, 2011 7:00 AM UTC
Merck KGaA's Merck Serono S.A. division acquired exclusive, worldwide rights to multiple sclerosis (MS) candidate PI-2301 from Peptimmune for $1.5 million. The biotech filed for Chapter 7 bankruptcy...